Results 171 to 180 of about 27,184 (256)

Longitudinal changes in estimated glomerular filtration rates in chronic hepatitis B patients treated with Tenofovir Alafenamide <i>vs</i> Entecavir. [PDF]

PeerJ
Li X, Wu Q, Huang F, Lai C, Chen F, Meng J, Wang F, Zeng H, Zhang L.   +8 more
europepmc   +1 more source

Deep sequencing analysis of hepatitis B virus in patients with incomplete response to tenofovir alafenamide fumarate treatment. [PDF]

World J Hepatol
Yamada N, Igarashi H, Murayama A, Suzuki M, Yasuda K, Saito M, Isogawa M, Kato T.   +7 more
europepmc   +1 more source

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. [PDF]

AIDS Res Ther
Daar ES, Orkin C, Sax PE, Hagins D, Pozniak A, Workowski K, Brinson C, Tiraboschi JM, Liu H, Deaton C, Cohen C, Madera S, Hindman JT, Ramgopal M.   +13 more
europepmc   +1 more source

Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study. [PDF]

Front Med (Lausanne)
Feng Y, Zhou L, Shi S, Wang Z, Wang X, Du F.   +5 more
europepmc   +1 more source

Efficacy and Safety of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide Fumarate in Treating Acute-on-Chronic Liver Failure with Hepatitis B Virus: A Network Meta-analysis. [PDF]

Infect Dis Ther
Liu J, Bi Y, Ma X, Xin Y.
europepmc   +1 more source

Comparison of efficacy and safety of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate treatment in patients with high viral load of hepatitis B virus. [PDF]

Medicine (Baltimore)
Zhang C, Chen X, Hong Z, Qi Y, Wang X, Dai Y, Qiu Y.   +6 more
europepmc   +1 more source

Long-term metabolic and safety profiles of tenofovir alafenamide and tenofovir disoproxil fumarate in ART-naive people living with HIV: a multicenter retrospective study using a mixed-effects model. [PDF]

BMC Pharmacol Toxicol
Karabay O, Vatan A, Ucar A, Yilmaz I, Balta NC, Kanturk A, Dumlu R, Cag Y, Caskurlu H, Şik MT, Otman ZA, Balci U, Senbayrak S, Akhan S, Deniz MT, Yekenkurul D, Ince N, Tunca B, Cakirca TD, Bastug A, Erkorkmaz U, Guclu E.   +21 more
europepmc   +1 more source

Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinion. [PDF]

Infez Med
Di Perri G, Bonora S.
europepmc   +1 more source